

## DAFTAR PUSTAKA

1. Aryani F, Sari O. Gambaran Pola Penggunaan Antipsikotik pada Pasien Skizofrenia di Ruang Rawat Inap Rumah Sakit Jiwa. *J Manaj dan Pelayanan Farm*. 2016;Volume 6 N:35–40.
2. Sugiarto, Yulastini M. Karakteristik Pasien Ekstrapiramidal Sindrom. *Adi Husada Nurs J*. 2020;6(2):106–11.
3. Julaeha. VDA, Pradana DA. Gambaran Efek Samping Antipsikotik pada Pasien Skizofrenia pada Bangsal Rawat Inap di Rumah Sakit Grhasia Yogyakarta. *Farmasains*. 2016;3(1):35–41.
4. Kementerian Kesehatan Republik Indonesia. Situasi Kesehatan Jiwa Di Indonesia. *InfoDATIN*. 2019. p. 12.
5. Khoiriyah R, Handayani S. Kesehatan Mental Emosional Perempuan Penderita Kanker di Indonesia. *Jkmm*. 2020;3(2):164–73.
6. Kementerian Kesehatan Republik Indonesia. Riset Kesehatan Dasar Provinsi Sumatera Barat Tahun 2018. Laporan Riskesdas Nasional 2018. 2018. 493 p.
7. Dania H, Faridah IN, Rahmah KF, Abdulah R, Barliana MI, Perwitasari DA. Hubungan Pemberian Terapi Antipsikotik terhadap Kejadian Efek Samping Sindrom Ekstrapiramidal pada Pasien Rawat Jalan di Salah Satu Rumah Sakit di Bantul, Yogyakarta. *Indones J Clin Pharm*. 2019;8(1).
8. Purwandityo AG, Febrianti Y, Sari CP, Ningrum VDA, Sugiarto OP. The Influence of Antipsychotic to Decrease the Score of The Positive and Negative Syndrome Scale-Excited Component. *Indones J Clin Pharm*. 2018;7(1):19–29.
9. Saharuddin, Ikawati Z, Kristanto CS. Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr. Ernaldi Bahar Palembang. 2021;17(2):206–16.
10. Hariyanto I, Putri RA, Untari EK. Different Type of Antipsychotic Therapies on Length of Stay of Acute Schizophrenia Patients in Sungai Bangkong Regional Mental Hospital Pontianak. *Indones J Clin Pharm*. 2016;5(2):115–22.
11. T. J, DiPiro, C. G, Yee L, Posey M. 11th Edition *Pharmacotherapy : A Pathophysiologic Approach*. 2020.
12. Istichomah FR. The Effectiveness of Family Knowledge About Schizophrenia Toward Frequency of Recurrence of Schizophrenic Family Members At Poly Mental Grhasia Mental Hospital D. I. Yogyakarta. *J Kesehat "Samodra Ilmu."* 2019;10(2):1689–99.
13. Putri GR, Ambarini TK. Gambaran Koping Stres dan Persepsi Dukungan

Keluarga Pada Pasien Skizofrenia Fase Remisi. *J Psikol Klin dan Kesehat Ment.* 2018;Vol. 7:25–36.

14. Nasional Institute of Mental Health. *Mental Disorders*. United States: Department of Health and Human Service National Institute of Health; 2021.
15. Hermiati D, Harahap RM. Faktor yang Berhubungan dengan Kasus Skizofrenia. *J Keperawatan Silampari.* 2018;1(2).
16. Sari P. Dinamika Psikologi Penderita Skizofrenia Paranoid Yang Sering Mengalami Relapse. *Psikoislamedia J Psikol.* 2019;4(2):124–36.
17. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia - An Overview. *JAMA Psychiatry.* 2020;77(2):201–10.
18. Chen L, Selvendra A, Stewart A, Castle D. Risk factors in early and late onset schizophrenia. *Compr Psychiatry.* 2018;80:155–62.
19. Stilo SA, Murray RM. Non-Genetic Factors in Schizophrenia. *Curr Psychiatry Rep.* 2019;21(100).
20. Zamanpoor M. Schizophrenia in a genomic era: A review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. *Psychiatr Genet.* 2020;1–9.
21. Wahyuni AS. *Bunuh Diri Pada Skizofrenia*. Denpasar; 2018.
22. Fatani BZ, Aldawod RA, Alhawaj FA. Schizophrenia: Etiology, Pathophysiology and Management: A Review. *Egypt J Hosp Med.* 2017;69(6):2640–6.
23. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. *Lancet.* 2016;388(10039):86–97.
24. Katona C, Cooper C, Mary R. *At a Glance Psikiatri*. Jakarta: Erlangga; 2012.
25. Khan FZ, Rashid N, Sultana SP, Rahman W, Nazrina S, Ara H. Treatment Response on Positive Symptoms of Schizophrenia with Olanzapine and Risperidone. *J Armed Forces Med Coll Bangladesh.* 2020;15(1):58–60.
26. Correll CU, Schooler NR. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatr Dis Treat.* 2020;16:519–34.
27. Trishna AR, Muhdi N. Clinical Manifestation Differences of Schizophrenia Patients Based on Gender. *J Psikiatri Surabaya.* 2020;9(1):14.
28. Miret S, Fatjó-Vilas M, Peralta V, Fañanás L. Basic symptoms in schizophrenia, their clinical study and relevance in research. *Rev Psiquiatr Salud Ment.* 2016;9(2):111–22.

29. American Psychiatric Association. Diagnostic And Statistical Manual of Mental Disorder Edition. Washinton DC: American Psychiatric Publishing. Washinton DC; 2013.
30. Kumalasari DN, Dwidiyanti M, Ediati A. Terapi Keperawatan Dalam Mengatasi Depresi Pada Pasien Skizofrenia: Literatur Review 1. J Keperawatan Jiwa. 2021;9(1):105–12.
31. Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. *Molecules*. 2018;23(8).
32. Ropper AH, Marder SR, Cannon TD. Schizophrenia *NEJM Review Marder*. *N Engl J Med*. 2019;18:1753–61.
33. Armand D. Analisis Persepsi Keputusan Pasien Pulang Atas Permintaan Sensiri (PAPS) Terhadap Mutu Pelayanan dan Kepuasan di Ruang Rawat Inap VIP RSUD Deli Serdang Tahun 2014. 2014.
34. Harjanti, Wulandari L. Analisis Angka Kejadian Readmission Kasus Skizofrenia. *J Manaj Inf Kesehat Indones*. 2018;6(2):169.
35. Masturoh I, Nauri TA. Metodologi Penelitian Kesehatan. Jakarta: Kementrian Kesehatan Republik Indonesia; 2018. 189–190 p.
36. Setyaningsih T, Fitria D, Supriyanah S. Hubungan Faktor-Faktor Yang Memengaruhi Kepatuhan Minum Obat Dengan Kepatuhan Pasien Skizofrenia Yang Mengalami Halusinasi Di Rs Husada. *J Kesehat Holist*. 2019;2(1):13–29.
37. Puskesmas K, Ii P, Fibriana AI. FAKTOR RESIKO TERJADINYA SKIZOFRENIA (Studi Kasus di Wilayah Kerja Puskesmas Pati II). *Public Heal Perspect J*. 2016;1(1):1–12.
38. Prihananto DI, Hadisaputro S, Adi MS. Faktor Somatogenik, Psikogenik, Sosiogenik yang Merupakan Faktor Risiko Kejadian Skizofrenia Usia < 25 Tahun (Studi di Kecamatan Kepil Kabupaten Wonosobo). *J Epidemiol Kesehat Komunitas*. 2018;3(2):69.
39. Oktaviani M A, Hari Basuki Notobroto. Perbandingan Tingkat Konsistensi Normalitas Distribusi Metode Kolmogorov-Smirnov, Lilliefors, Shapiro-Wilk, dan Skewness-Kurtosis. *J Biometrika dan Kependud*. 2014;3(2):127–35.
40. Quraisy A. Normalitas Data Menggunakan Uji Kolmogorov-Smirnov dan Saphiro-Wilk. *J-HEST J Heal Educ Econ Sci Technol*. 2020;3(1):7–11.
41. Dewi ETK, Agoestanto A, Sunarmi. Metode Least Trimmed Square (LTS) dan MM- Estimation untuk Mengestimasi Parameter Regresi Ketika Terdapat Outlier. 2016;5(1).
42. Purnomo H, Syamsul ES. Statistika Farmasi (Aplikasi Praktis dengan SPSS). Yogyakarta: CV Grafika Indah; 2017. 212 p.

43. Naheed M, Akter KA, Tabassum F, Mawla R, Rahman M. Factors contributing the outcome of Schizophrenia in developing and developed countries: A brief review. *Int Curr Pharm J.* 1970;1(4):81–5.
44. Ahmed S, Khan AM, Mekala HM, Venigalla H, Ahmed R, Etman A, et al. Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis. *Heliyon* 2017;3(11):e00429.
45. Saucedo Uribe E, Carranza Navarro F, Guerrero Medrano AF, García Cervantes KI, Álvarez Villalobos NA, Acuña Rocha VD, et al. Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis. *J Psychiatr Res* 2020;129:222–33. Available from: <https://doi.org/10.1016/j.jpsychires.2020.06.013>
46. Chen YL, Chen KP, Chiu CC, Tai MH, Lung FW. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. *BMC Psychiatry.* 2018;18(1):1–8.
47. Fleischhacker WW. Second-generation antipsychotics: Are their similarities greater than their differences? *Eur Psychiatry.* 2003;18(SUPPL. 2):38s-45s.
48. Lanzi R, Menculini G, Bachetti MC, Moretti P, Tortorella A. Differential gender severity expression of symptoms in patients with dual diagnosis: An in-patient observational study. *Psychiatr Danub.* 2020;32:S70–4.

